Navigation Links
T2 and collaborators announce discovery of novel clot structure biology enabled by T2HemoStat
Date:1/9/2014

Lexington, MA, January 9, 2014 T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat. T2HemoStat is an innovative diagnostic tool for assessing blood clotting, platelet function, fibrinolytic activity and hematocrit measurements from a fingerstick blood sample in about 15 minutes. T2HemoStat uniquely detects millions of data points during a blood coagulation cascade. Researchers at the University of Pennsylvania, utilizing T2HemoStat, detected a signature of a novel clot structure, never before described in scientific literature. This clot structure involves a conformational change in red blood cell structure, termed polyhedrocytes. The presence of these structures could make stroke and heart attack victims less responsive to medications.

Blood clots are made up of fibrin, platelets and erythrocytes. Before now, little was known about the internal structure of contracted clots or the role that erythrocytes play in the contraction process. T2HemoStat is the first diagnostic method to enable the detection of this unique clot structure where erythrocytes are closely packed as polyhedra (polyhedrocytes) to form a seemingly impermeable barrier. This barrier means that these clot structures may be less susceptible to certain medications, called fibrinolytics, used to break up blood clots in the treatment of heart attacks and strokes.

"Physicians treating the millions of patients at risk for thrombosis and bleeding, including after surgery or trauma, are in need of a more convenient method to provide up to the minute results of key hemostatic parameters," commented co-author Douglas B. Cines, MD, Professor of Pathology and Laboratory Medicine and Director of the Special Coagulation Laboratory, Perelman School of Medicin
'/>"/>

Contact: Kari Watson
kwatson@macbiocom.com
781-235-3606
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. WHOI researchers, collaborators receive $1.4 million grant to study life in oceans greatest depths
2. Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
3. MARC travel awards announced for the APS 2014 Professional Skills Training Course
4. CROS NT Ltd Announces Acquisition of MDSL International Ltd.
5. FacialNetwork.com Announces Beta Release Of "NameTag" The First Real-Time Facial Recognition App For Google Glass
6. HGH Supplements Information Website HGH.us.com Announces New Discounts on Sytropin and Genf20 Plus
7. BBSRC announces £10M of funding for advanced scientific equipment
8. Life Sciences Discovery Fund announces R&D grants
9. Genetics Society of America announces recipients of spring 2014 DeLill Nasser Award
10. CROS NT Ltd Announces Appointment of Andrew MacGarvey as CEO
11. Biophysical Society announces speakers for Future of Biophysics Burroughs Wellcome Fund Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... leaves, photosystem 1 (PS1) absorbs light and its ... carbon dioxide to biomass. Photovoltaic devices, mostly build ... but produce electricity. One approach for the development ... the semi-conductor with the isolated membrane protein complexes ... a highly stable PS1 from thermophilic cyanobacteria that ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... This news release is available in German . ... power are inherently intermittent energy sources. If a large amount ... in the future, excess energy will have to be stored ... for. However, existing storage capacities are far from adequate for ... better technologies. One important focus lies on battery systems that ...
Breaking Biology News(10 mins):A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... A) today announced that its breakthrough Human Genome CGH ... Peter MacCallum Cancer Centre in a three-year study designed ... lining of the chest, the abdominal cavity and around ... Due to its active mining and manufacturing of asbestos ...
... The human fossil evidence from the Mladec Caves in Moravia, ... proven for the first time, through modern radiocarbon dating, to ... modern humans in Europe. , A team of researchers from ... Vienna in Austria and from the Washington University in St. ...
... Studying phage, a primitive class of virus that infects ... researchers have gained insight into the driving force behind ... in the past to occur through the release of ... all phages (also known as bacteriophages) are formed of ...
Cached Biology News:Agilent Technologies new genome analysis technology set to accelerate Australia fight against mesothelioma 2Oldest cranial, dental and postcranial fossils of early modern European humans confirmed 2Basis for DNA ejection from single phage particles 2
(Date:8/19/2014)... (PRWEB) August 19, 2014 Robin Williams’ ... disease can take on an individual. Symptoms range ... facial expression, problems swallowing and severe depression. Parkinson’s ... dying off of dopamine producing neurons of the brain. ... a disease that slowly and progressively gets worse, they ...
(Date:8/19/2014)... 2014 CSSi, the leader in patient recruitment ... formation of the company,s Medical and Clinical Advisory Board ... Dr. William E. Gannon, Jr. to the ... The MCAB, with Dr. Gannon,s leadership, will ... and set strategic goals for the advancement and development ...
(Date:8/19/2014)... 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the ... of its Oral Amphotericin B (Oral Amp B) ... conducted by ImmuneCarta®, the immune monitoring business unit ... of Oral Amp B in reactivating latent HIV ... intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... ... most complex toxicology study designs in South Korea , ... Cedar Knolls, NJ and Daejeon, South Korea (PRWEB) ... solutions and the developer of Pristima™ the premier preclinical solution on the market, is ...
... , , ABBOTT PARK, Ill., Aug. ... expansion of the company,s XIENCE V(R) USA post-approval study designed to ... Everolimus Eluting Coronary Stent System in a real-world clinical setting out ... from the XIENCE V USA trial to be eligible to cross ...
... , , , ... MON ) R&D pipeline is on the verge of a technology ... for growers and has the company poised to meet its goals ... and president, will tell investors today. , , ...
Cached Biology Technology:Korea Institute of Toxicology Implementing Xybion's Pristima™ 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 2Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 3Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 2Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 3Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 4Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 5Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 6Monsanto Is on the Verge of a Technology Explosion, Executives Tell Investors at Annual Field Event 7
...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant canine ... culture supernates and serum.1 Each kit contains ... fifteen 96-well plates, provided that the following ...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu™ Insertion Kit...
Biology Products: